Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06093828
NA

Transcatheter Treatment of Tricuspid Valve Regurgitation

Sponsor: TriFlo Cardiovascular, Inc.

View on ClinicalTrials.gov

Summary

Tricuspid Regurgitation induces an asymmetric enlargement of the tricuspid valve (TV) annulus causing a reduction of leaflets coaptation. Annular dilation continues even after surgical treatment. The progressive nature of TR, inadequate surgical treatment, and high-risk patient population make TR an ideal target for transcatheter therapy. The TriFlo TFO System introduces a new concept for the treatment of tricuspid regurgitation. Its commissural anchoring is designed to respect TV leaflet integrity, mobility, and maintain RV contractility.

Official title: Transcatheter Treatment of Tricuspid Valve Regurgitation With the TriFlo Tricuspid Flow Optimizer (TFO) System

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-10

Completion Date

2031-12

Last Updated

2023-10-23

Healthy Volunteers

No

Interventions

DEVICE

TriFlo Tricuspid Flow Optimizer

An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.

Locations (4)

Pineta Grande Hospital

Castel Volturno, Caserta, Italy

IRCCS Humanitas Research Hospital

Rozzano, Milano, Italy

IRCCS Policlinico San Donato

San Donato Milanese, Milano, Italy

Policlinico Campus Biomedico

Roma, Italy